2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Pediatric, Pregnant
PAPER

2670 Disparities in publication outcomes for sickle cell disease research in blood

Hannah Kate Lebensburger, Kathryn Ashley Whelan2, Ruby Lefkowitz3, Chibuzo Ilonze, MD, MPH4, Ana Xavier, MD, PhD5
1 University of Alabama Birmingham, Birmingham, Alabama, United States
2 University of Alabama Birmingham, Birmingham, Alabama, United States
3 University of Alabama Birmingham, Birmingham, Alabama, United States
4 University of Alabama Birmingham, Birmingham, Alabama, United States
5 University of Alabama Birmingham, Birmingham, Alabama, United States

Background:
Despite advances in disease modifying and curative therapies, and outcomes research in sickle cell disease (SCD), concerns persist as to whether SCD studies meet the Blood publication criteria for being both definitive and novel. To determine whether SCD research was proportionally represented, we reviewed publications in Blood and Blood Advances throughout 2025.

Methods:
A PubMed search was conducted using the query "Blood"[ta] OR "Blood Advances"[ta] for articles published between January 1, 2025, and December 31, 2025. Articles were manually screened to select original research and review articles. Non-research article types were excluded (specifically: Advances Snapshot, Advances Viewpoint, Blood Spotlight, Blood Works, CME Commentary, Drug Advances, Editorial, Errata/Erratum, Inside Blood Advances Review Series Overview, Inside Blood, Perspective, and Response). Included articles were categorized by journal-specified headings and by investigators across five domains: 1) Malignant vs. Classical hematology, 2) Clinical vs. Basic/Translational, 3) Pediatric vs Adult populations, 4) Broad hematology subspecialty category, and 5) Specific disease state. Article distributions were compared using descriptive statistics and chi-square tests (p<0.05; JMP Student Edition).

Results:
Of 1,667 screened articles, 1,046 were included in the final analysis (Blood, n=456; Blood Advances, n=590). Overall, 327 (31%) addressed Classical hematology and 719 (69%) addressed Malignant hematology. The distribution between Classical vs. Malignant hematology was similar across both journals (Blood: 30.5% classical vs. Blood Advances: 31.9% classical, p=0.63). Similarly, review articles (n=65 total: 32% Classical, 68% Malignant) showed no significant difference between journals (p=0.81). Of 37 “How I Treat” articles published in Blood, 14 (37%) were Classical hematology, with only 1 focusing on SCD. Disparities in publications outcomes emerged within the 175 “Clinical Trials and Observations” articles, where only 31 (17%) were Classical hematology. Furthermore, malignant studies in the “Clinical Trials and Observations” category were significantly more likely to be published in Blood than classical studies (45% vs. 19%; p=0.006). Representation in Blood varied considerably by Classical disease category. High rates of publication in Blood (vs. Blood Advances) were observed in Transfusion Medicine (88%), Hematopoiesis (60%), Red Blood Cell/Iron Disorders (58%), Bone Marrow Failure (46%), Bleeding Disorders (42%), and Thrombosis (42%). Conversely, hemoglobinopathies yielded 53 total publications in 2025, with only 12 (23%) articles published in Blood. Specifically, for SCD (n=43 total), only 9 (21%) articles were published in Blood across 8 distinct headings (Red Cell/Iron/Erythropoiesis [n=2], Clinical Trials/Observations [n=1], Gene Therapy [n=1], Plenary Paper [n=1], Special Report [n=1], Transfusion Medicine [n=1], Letter [n=1], and “How I Treat” [n=1]); four of these were clinical studies (2 Adult, 2 Adult/Pediatric). Blood Advances published 34 SCD articles, primarily under Red Cell  Biology (n=14), Research Letters (n=8), and Clinical Trials and Observations (n=5).

Conclusions:
In 2025, Classical Hematology comprised just 31% of articles published in Blood and Blood Advances. Notably, Classical Hematology “Clinical Trials and Observations” studies were significantly less likely to appear in Blood than their malignant counterparts, with SCD representing the lowest acceptance proportion among classical categories. These disparities highlight persistent publishing barriers for SCD research in premier ASH journals and point to an urgent need to re-evaluate journal editorial metrics and review priorities for Classical hematology.

Hannah Kate Lebensburger: No relevant conflicts of interest to declare.